NCT03125928View on ClinicalTrials.gov

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

Atezolizumab

Monoclonal antibody

DRUG

Paclitaxel

Chemotherapy

DRUG

Trastuzumab

Monoclonal antibody

DRUG

Pertuzumab

Monoclonal antibody

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Fox Chase Cancer Center

OTHER